Danielle B Ulanet
Overview
Explore the profile of Danielle B Ulanet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
So J, Lewis A, Smith L, Stanley K, Franich R, Yoannidis D, et al.
EMBO Mol Med
. 2022 May;
14(7):e15203.
PMID: 35514210
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) catalyzes one of the rate-limiting steps in de novo pyrimidine biosynthesis, a pathway that provides essential metabolic precursors for nucleic acids, glycoproteins, and phospholipids....
2.
McDonald G, Chubukov V, Coco J, Truskowski K, Narayanaswamy R, Choe S, et al.
Mol Cancer Ther
. 2020 Oct;
19(12):2502-2515.
PMID: 33082276
Agents targeting metabolic pathways form the backbone of standard oncology treatments, though a better understanding of differential metabolic dependencies could instruct more rationale-based therapeutic approaches. We performed a chemical biology...
3.
Allen E, Ulanet D, Pirman D, Mahoney C, Coco J, Si Y, et al.
Cell Rep
. 2016 Oct;
17(3):876-890.
PMID: 27732861
Although aberrant metabolism in tumors has been well described, the identification of cancer subsets with particular metabolic vulnerabilities has remained challenging. Here, we conducted an siRNA screen focusing on enzymes...
4.
Ulanet D, Couto K, Jha A, Choe S, Wang A, Woo H, et al.
PLoS One
. 2014 Dec;
9(12):e115144.
PMID: 25502225
Recent work has highlighted glutaminase (GLS) as a key player in cancer cell metabolism, providing glutamine-derived carbon and nitrogen to pathways that support proliferation. There is significant interest in targeting...
5.
Ulanet D, Hanahan D
PLoS One
. 2010 Sep;
5(8):e12454.
PMID: 20805995
The Arf tumor suppressor acts as a sensor of oncogenic signals, countering aberrant proliferation in large part via activation of the p53 transcriptional program, though a number of p53-independent functions...
6.
Ulanet D, Ludwig D, Kahn C, Hanahan D
Proc Natl Acad Sci U S A
. 2010 May;
107(24):10791-8.
PMID: 20457905
The type 1 insulin-like growth factor receptor (IGF-1R) tyrosine kinase is an important mediator of the protumorigenic effects of IGF-I/II, and inhibitors of IGF-1R signaling are currently being tested in...
7.
Hager J, Ulanet D, Hennighausen L, Hanahan D
PLoS One
. 2009 Feb;
4(2):e4455.
PMID: 19209227
Tumor cell death is modulated by an intrinsic cell death pathway controlled by the pro- and anti-apoptotic members of the Bcl-2 family. Up-regulation of anti-apoptotic Bcl-2 family members has been...
8.
Ulanet D, Flavahan N, Casciola-Rosen L, Rosen A
Arthritis Rheum
. 2004 Jan;
50(1):233-41.
PMID: 14730621
Objective: To investigate the association of specific autoantibodies with distinct disease phenotypes. The association of autoantibodies to nucleophosmin/B23 with pulmonary hypertension in scleroderma, and the susceptibility of autoantigens to cleavage...
9.
Ulanet D, Torbenson M, Dang C, Casciola-Rosen L, Rosen A
Proc Natl Acad Sci U S A
. 2003 Oct;
100(21):12361-6.
PMID: 14519847
The association of a specific autoantibody response with distinct disease phenotypes is observed in both autoimmune diseases and cancer. Although the underlying mechanisms remain unclear, it is likely that unique...
10.
Ulanet D, Wigley F, Gelber A, Rosen A
Arthritis Rheum
. 2003 Feb;
49(1):85-92.
PMID: 12579598
Objective: To determine whether the abundant nucleolar phosphoprotein B23 is a target of autoantibodies in scleroderma, and to examine the clinical phenotype associated with these antibodies. Methods: Ninety-two randomly selected...